RedHill Biopharma Divests Talicia to Apotex for $18M Upfront

What happened

RedHill Biopharma Ltd. (NASDAQ: RDHL), a specialty biopharmaceutical company focused on gastrointestinal drugs, announced it has divested its Talicia business to a subsidiary of Apotex Health Corp. The deal includes $18 million in upfront cash and up to an additional $35 million in payments tied to worldwide net sales milestones, according to a press release carried by PR Newswire and reports from Kalkine Media and The Fly.

The company transferred its 70% stake in Talicia; Apotex already owned the remaining 30% through its earlier acquisition of Cumberland Pharmaceuticals' interest, as noted by All Penny Stocks. RedHill shares rose on the news, trading up 1.54% to $0.724 on the event date, though other reports noted a larger intraday move.

The reported development has not yet been filed with the SEC, so no regulatory filing exists for this transaction at the time of this article. The company's press release is the primary source.

Why it matters

For RedHill, the divestiture provides non-dilutive cash — $18 million upfront — plus potential future milestone payments. This is material for a small biotech, as it bolsters the balance sheet without issuing new shares.

The deal also sheds a commercial asset, allowing RedHill to focus on its other pipeline and commercial products. The structure (cash plus sales-based milestones) suggests Apotex will take over commercialization of Talicia, and RedHill benefits if sales hit agreed targets.

What this means

Talicia is an antibiotic combination therapy for Helicobacter pylori infection in adults, a gastrointestinal condition. RedHill's press release and third-party reports describe the transaction as a divestiture — the sale of a business segment or product line.

The $18 million upfront is cash RedHill receives at closing. The up-to-$35 million in milestones are future payments contingent on Talicia's worldwide net sales reaching certain thresholds; these are not guaranteed and depend on product performance.

This is a typical asset sale for a smaller drugmaker looking to raise capital without diluting shareholders. The stock's positive reaction reflects investor relief that the company secured cash and reduced its commercial obligations. Going forward, RedHill will likely use the proceeds to fund its remaining pipeline, though the company has not detailed specific plans in the verified sources.